New pill tested for rare brain tumor disorder
NCT ID NCT07131722
Summary
This early-stage study is testing a new oral medication called PRG-N-01 for adults with Neurofibromatosis Type II (NF2), a genetic condition that causes non-cancerous tumors along nerves. The main goals are to find the safest and most effective dose and to see if the drug can shrink tumors or improve symptoms like hearing loss. About 25 participants will take the pill daily for up to 96 weeks while doctors monitor their health and tumor size.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS TYPE II are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.